Physician profile
Anna Drosou
NPI 1629009196
$5,222.93
in general payments reported to CMS, 2019-2025
33 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what 76% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $539 · 2021: $746 · 2022: $867 · 2023: $647 · 2024: $952 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.09 |
| Education | $149.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,283.74 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Genzyme Corporation | $514.14 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $424.76 | 2020-2024 | Libtayo, Dupixent |
| Genentech USA, INC. | $254.15 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $237.92 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $228.57 | 2019-2025 | |
| Dermavant Sciences, INC. | $212.21 | 2024 | Vtama |
| Lilly USA, LLC | $190.21 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Almirall LLC | $189.96 | 2020-2023 | Klisyri, Seysara |
| Incyte Corporation | $180.84 | 2021-2023 | Opzelura |
| Janssen Biotech, INC. | $176.70 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $168.23 | 2020-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $160.45 | 2019-2023 | |
| Arcutis Biotherapeutics, INC. | $133.89 | 2023-2025 | Zoryve |
| Organon LLC | $119.46 | 2025 | Vtama |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $112.97 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $111.69 | 2019-2025 | Nemluvio |
| Amgen INC. | $85.44 | 2022-2023 | Otezla |
| Vyne Pharmaceuticals INC. | $74.81 | 2020-2021 | |
| Leo Pharma INC. | $48.27 | 2019-2022 | |
| Biocon Biologics INC | $44.47 | 2025 | Yesintek |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.64 | 2022-2023 | Jublia, Duobrii, Arazlo |
| Revance Therapeutics, INC. | $34.00 | 2024 | Daxxify |
| Sandoz INC. | $31.38 | 2025 | Hyrimoz |
| Celgene Corporation | $24.24 | 2019 | |
| Springworks Therapeutics, INC. | $22.62 | 2025 | Gomekli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.38 | 2024 | Cyltezo |
| Biofrontera INC. | $19.84 | 2019 | |
| Sebela Pharmaceuticals INC. | $16.51 | 2021 | |
| Pfizer INC. | $16.24 | 2019 | |
| Nobelpharma America, LLC | $15.60 | 2025 | |
| Misonix INC | $14.05 | 2019 | |
| Convatec INC. | $13.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Drosou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.